Rituxan plus Temodar Effective for Primary Central Nervous System Lymphoma

Researchers from Italy have reported that the combination of Rituxan (rituximab) and Temodar (temozolomide) is an effective treatment regimen for patients with primary central nervous system (CNS) non-Hodgkin’s lymphoma (NHL). This phase II study was presented at the 2005 meeting of the American Society of Clinical Oncology in Orlando, Florida, May 13-17 2005.

Primary central nervous system lymphoma is a relatively uncommon form of (NHL) that has been increasing in incidence over the past three decades. Unlike the progress made in general NHL treatment, there has been little progress in the treatment of CNS NHL. The standard treatment has been high-dose methotrexate and whole-brain radiotherapy. However, treatment-related neurotoxicity is common, especially in the elderly. Temodar is an alkylating agent used to treat primary and secondary brain tumors, especially glioblastoma multiforme.

More can be found in this article.

LymphomaInfo Social